AG-METOPROLOL-L TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

METOPROLOL TARTRATE

Dostupné s:

ANGITA PHARMA INC.

ATC kód:

C07AB02

INN (Mezinárodní Name):

METOPROLOL

Dávkování:

50MG

Léková forma:

TABLET

Složení:

METOPROLOL TARTRATE 50MG

Podání:

ORAL

Jednotky v balení:

100/500

Druh předpisu:

Prescription

Terapeutické oblasti:

BETA-ADRENERGIC BLOCKING AGENTS

Přehled produktů:

Active ingredient group (AIG) number: 0111923002; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2018-10-02

Charakteristika produktu

_AG-Metoprolol-L tablets _
_Page 1_
_ _
_of 41_
_ _
PRODUCTMONOGRAPH
PR
AG-METOPROLOL-L
Metoprolol Tartrate Tablets USP
25mg, 50 mg and 100 mg film coated tablets,
USP
β-Adrenergic Receptor Blocking Agent
Angita Pharma Inc
1310 rue Nobel
Boucherville, Québec
J4B 5H3, Canada
Submission Control No: 266208
Date
of
Revision:
August 10, 2022
_AG-Metoprolol-L tablets _
_Page 2_
_ _
_of 41_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT
INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND
PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
12
DOSAGE AND ADMINISTRATION
...............................................................................
18
OVERDOSAGE
.................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 21
STORAGE AND STABILITY
..........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 25
PART II: SCIENTIFIC
INFORMATION ..................................................................................
26
PHARMACEUTICAL INFORMATION
..........................................................................
26
CLINICAL TRIALS
...................................................................